Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company continues with human trials, and we are looking forward to the initial results and suggest investors consider investing ahead of the result release.
